Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy

Author:

Fujiwara Keiichi1,Hasegawa Kosei1,Nagao Shoji2

Affiliation:

1. Department of Gynecologic Oncology Saitama Medical University International Medical Center Saitama Japan

2. Department of Gynecology Hyogo Cancer Center Hyogo Japan

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference21 articles.

1. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first‐line interventions;Karam A;Ann Oncol,2017

2. Long‐term results of dose‐dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open‐label trial;Katsumata N;Lancet Oncol,2013

3. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO‐7): a randomised, multicentre, open‐label, phase 3 trial;Pignata S;Lancet Oncol,2014

4. Weekly vs. every‐3‐week paclitaxel and carboplatin for ovarian cancer;Chan JK;N Engl J Med,2016

5. ICON8: a GCIG phase III randomised trial evaluating weekly dose‐dense chemotherapy integration in first‐line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results of primary progression‐free survival (PFS) analysis [abstract 929O_PR];Clamp A;Ann Oncol,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3